Targeting the universal T-cell marker CD7, this strategy involves the expression of anti-CD7 CAR through lentiviral transduction, CRISPR-Cas9 for CD7, and TCR alpha chain (TRAC) ablation to avoid fratricide and GVHD, respectively (250). This evidence concerns the gene TRAC and graft versus host disease.